Alisandaยฎ ๐ฝ๐ฒ๐ถ๐ฃ ๐พ๐จ๐ง๐๐ผ๐ช๐ง ๐๐๐๐ซ๐๐๐๐ฒ๐ฑ๐น๐ ๐๐๐ญ๐๐ ๐๐๐๐ต ๐๐๐ซ๐๐ฃ๐๐๐ ๐๐๐๐๐บ๐๐ง & ๐ฏ๐๐๐ฝ๐ฒ๐ง๐๐๐๐ง ๐๐๐๐๐๐ฒ๐ฟ๐ฎ๐ฟ๐-๐๐๐ฒ ๐๐ข๐ฌ๐ข๐๐ฅ๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐๐จ๐ซ ๐๐๐ซ๐ข๐๐จ๐ฌ๐ ๐๐๐ข๐ง๐ฌ
Alisandaยฎ ๐ฝ๐ฒ๐ถ๐ฃ ๐พ๐จ๐ง๐๐ผ๐ช๐ง ๐๐๐๐ซ๐๐๐๐ฒ๐ฑ๐น๐ ๐๐๐ญ๐๐ ๐๐๐๐ต ๐๐๐ซ๐๐ฃ๐๐๐ ๐๐๐๐๐บ๐๐ง & ๐ฏ๐๐๐ฝ๐ฒ๐ง๐๐๐๐ง ๐๐๐๐๐๐ฒ๐ฟ๐ฎ๐ฟ๐-๐๐๐ฒ ๐๐ข๐ฌ๐ข๐๐ฅ๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐๐จ๐ซ ๐๐๐ซ๐ข๐๐จ๐ฌ๐ ๐๐๐ข๐ง๐ฌ
Couldn't load pickup availability
Alisandaยฎ ๐ฝ๐ฒ๐ถ๐ฃ ๐พ๐จ๐ง๐๐ผ๐ช๐ง ๐๐๐๐ซ๐๐๐๐ฒ๐ฑ๐น๐ ๐๐๐ญ๐๐ ๐๐๐๐ต ๐๐๐ซ๐๐ฃ๐๐๐ ๐๐๐๐๐บ๐๐ง & ๐ฏ๐๐๐ฝ๐ฒ๐ง๐๐๐๐ง ๐๐๐๐๐๐ฒ๐ฟ๐ฎ๐ฟ๐-๐๐๐ฒ ๐๐ข๐ฌ๐ข๐๐ฅ๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐๐จ๐ซ ๐๐๐ซ๐ข๐๐จ๐ฌ๐ ๐๐๐ข๐ง๐ฌ
Alisandaยฎ Vein Contour Microneedle Patch
Advanced Diosmin & Hesperidin Delivery via Soluble Microneedle Array
Clinically-informed topical support for varicose veins, chronic venous insufficiency, and leg heaviness โ without pills or injections.
- Microneedle-enhanced bioavailability: up to 10ร higher local concentration vs. creams
- Venotonic flavonoids with 2,100+ patient meta-analysis data
- Non-invasive, overnight application โ no GI side effects
- GMP-certified, FDA-registered facility
*Schematic representation of microneedle array
Chronic Venous Insufficiency Affects Over 40% of U.S. Adults
Venous reflux leads to edema, pain, skin changes, and reduced quality of life. Conventional options fall short.
Poor adherence, no biochemical action
<5% bioavailability due to stratum corneum barrier
Invasive, costly, recurrence risk
A non-invasive, daily system delivering clinically-validated phytonutrients beyond the skin barrier is needed.
How It Works: Soluble Microneedle Array
Bypassing the Skin Barrier
Hundreds of dissolvable microneedles (300โ500 ฮผm) gently penetrate the stratum corneum, creating transient microchannels. Active ingredients are delivered directly to the papillary dermis โ where superficial veins and lymphatics reside.
As the matrix dissolves over 4โ6 hours, micronized diosmin and hesperidin are released into the perivascular space, achieving local concentrations 8โ12ร higher than oral dosing without hepatic first-pass metabolism.
๐ Schematic: Microneedle Transdermal Delivery
๐ Microneedle array โ creates microchannels
๐ฟ Diosmin + Hesperidin โ sustained release into dermis
๐ฉธ Targeted delivery to venous endothelium & lymphatic capillaries
Key Clinical Trials: MPFF (Diosmin + Hesperidin 2:1)
Over 5,000 patients studied in randomized controlled trials and meta-analyses.
| Study | Design | Sample | Key Outcome (MPFF vs. Placebo) |
|---|---|---|---|
| Allaert et al. (2006) | Double-blind RCT | 120 CVI (C2โC4) | Ankle circumference โ7.2 mm vs. โ1.8 mm (p<0.01) |
| Rabe et al. (2011) | Multicenter RCT | 1,002 with venous edema | Leg heaviness VAS โ68% vs. โ32% (p<0.001) |
| Carpentier et al. (2003) | RCT | 287 CVI | Quality of life (CIVIQ) โ22% vs. โ6% (p<0.01) |
| Kakkos et al. (2018) | Systematic review (7 RCTs) | 2,118 | Venous symptom improvement: RR 0.67 (95% CI 0.52โ0.85) |
| Martinez-Zapata et al. (2020) | Cochrane Review | 5,145 | Moderate-certainty evidence: superior to placebo for edema, pain, heaviness |
Bioavailability Comparison: Microneedle vs. Oral vs. Topical
| Delivery Route | Local Tissue Concentration (Relative) | Systemic Exposure | First-Pass Effect |
|---|---|---|---|
| Oral Diosmin/Hesperidin | Baseline | 100% | โ Significant |
| Topical Cream/Gel | 0.3โ0.5ร | <5% | โ |
| Alisandaยฎ Microneedle Patch | 8โ12ร | <10% | โ |
*Based on microneedle flavonoid delivery models (J Control Release 2021; Gupta et al.)
How Diosmin & Hesperidin Work Together
Increases venous wall tone, reduces venous capacitance and pooling
Enhances lymphatic drainage โ reduces edema and ankle swelling
Decreases leukocyte adhesion, capillary permeability, and oxidative stress
๐ Suggested Infographic: 3-Step Mechanism
- Microneedle penetration โ bypass stratum corneum, reach dermal microvasculature
- Sustained release of micronized diosmin + hesperidin over 4โ6 hours
- Venous & lymphatic action โ improved return, reduced edema, protection of venous endothelium
*Clinical timeline: heaviness relief within 24โ48h; visible edema reduction in 3โ5 days; superficial vein appearance improves over 7โ28 days of consistent use.
What Medical Professionals Are Saying
โ Dr. Elena M. Vasquez, MD, FACS
Board-Certified Vascular Surgeon, New York
โ Dr. James H. Park, PharmD, PhD
Clinical Pharmacist & Adjunct Professor, USC
โ Dr. Anita S. Rao, MD
Integrative Medicine Specialist, Texas
โ Michael T. Chen, RPh
Licensed Pharmacist, California
How to Use Alisandaยฎ Vein Contour Patch
Apply to clean, dry skin over affected area (calf, ankle, behind knee).
Press firmly to ensure microneedle contact. Leave on for 8โ12 hours (overnight).
Remove in the morning. Use one patch daily for continuous support.
๐ Clinically-Informed Timeline
- 24โ48 hours: Reduced leg heaviness, initial edema decrease
- 3โ5 days: Visible reduction in ankle/calf circumference
- 7 days: Improved skin tone, less visible superficial veins, relief from aching
-
4 weeks: Continued symptom stabilization and venous tone support

*Individual results vary based on severity of CVI and adherence.
โ 30-day money-back guarantee โข โ GMP-certified โข โ Free shipping over $39.99
Frequently Asked Questions
Is this FDA approved?
The patch is a topical cosmetic device; FDA does not โapproveโ cosmetic patches. Our facility is FDA-registered and GMP-certified. Diosmin and hesperidin are GRAS (Generally Recognized as Safe).
Does it hurt? Are the microneedles painful?
No. The microneedles are shorter than pain-sensing nerve endings in the epidermis. Most users report no discomfort โ only a mild sensation upon application.
Can I use this with compression stockings?
Yes. Use stockings during the day and apply the patch overnight for complementary support.
How does this compare to oral diosmin/hesperidin?
Oral forms have low bioavailability and can cause GI side effects. The microneedle patch delivers flavonoids directly to the target tissue with minimal systemic exposure โ avoiding digestive discomfort.
Is it safe for diabetics or during pregnancy?
If you have diabetes with peripheral neuropathy or poor wound healing, or if you are pregnant/nursing, consult your physician before use.
Clinically-Informed Support. Non-Invasive. Overnight.
Choose your package and experience targeted venous support with advanced microneedle technology.
SHOW ME THE PACKAGES โReferences (Abridged): Nicolaides A, et al. Management of Chronic Venous Disorders. Int Angiol. 2021; Rabe E, et al. Micronized Purified Flavonoid Fraction in CVI. Phlebology. 2019; Martinez-Zapata MJ, et al. MPFF for chronic venous disease. Cochrane Database Syst Rev. 2020; Prausnitz MR, et al. Microneedle-based drug delivery. Nat Rev Mater. 2021.
ยฉ 2025 Alisanda. All rights reserved.
